Get an alert when GLAXO OPERATIONS UK LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2027-05-04 (in 1y)

Last made up 2026-04-20

Watchouts

None on the register

Cash

Latest balance sheet

Net assets

£1B

+1.4% vs 2023

Employees

3,296

+2.6% vs 2023

Profit before tax

£31M

+49.7% vs 2023

Name history

Renamed 1 time since incorporation

  1. GLAXO OPERATIONS UK LIMITED 1978-12-31 → present
  2. GLAXO LABORATORIES LIMITED 1962-01-01 → 1978-12-31

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £659,082,000£825,617,000
Operating profit £28,427,000£39,933,000
Profit before tax £20,666,000£30,938,000
Net profit £7,131,000£13,877,000
Cash
Total assets less current liabilities £1,028,178,000£1,040,664,000
Net assets £1,014,273,000£1,028,150,000
Equity £1,014,273,000£1,028,150,000
Average employees 3,2143,296
Wages £279,770,000£285,390,000

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin 4.3%4.8%
Net margin 1.1%1.7%
Return on capital employed 2.8%3.8%
Gearing (liabilities / total assets) 31.6%35.2%
Current ratio 0.52x0.57x
Interest cover 2.90x3.01x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 101
Reporting scope
Standalone (parent only)
Auditor
Deloitte LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The Directors have taken into account that as part of the Group, the Company has already received the necessary letter of support from GlaxoSmithKline Finance plc and can take actions to ensure business continuity through operational channels, as well as the ability to manage variable costs. On the basis of those considerations, the Directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.”

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

5 active · 43 resigned

Name Role Appointed Born Nationality
WHYTE, Victoria Anne Secretary 1998-12-18 British
EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED Corporate Secretary 2006-08-31
OLIINYK, Dmytro Director 2022-02-19 Jun 1983 Ukrainian
SPEAR, Paul Andrew Director 2020-08-25 Jun 1974 British
EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED Corporate Director 2024-07-08
Show 43 resigned officers
Name Role Appointed Resigned
BICKNELL, Simon Michael Secretary 1994-11-24 1998-12-18
CHRISTIAN, Christopher Lindsay Secretary 1994-11-24
STEPHENS, Richard James Secretary 2003-07-21 2007-03-05
ADCOCK, Matthew Creighton Director 2013-04-09 2014-07-01
BAKER, Christopher, Dr Director 1993-05-23
BAXTER, Jeffrey Royston Director 1997-05-02 2001-12-19
BELL, Alan Menzies, Dr Director 1999-01-01 2001-12-30
BLAKER, Graham Joseph, Dr Director 1998-06-01
BRUCE, Paul Lawrence Director 1997-09-15 1998-12-18
BURNS, Alan George Director 2017-05-05 2019-05-08
CALDWELL, Joseph, Dr Director 1997-01-20 1998-08-19
CALLIANO, Riccardo Director 2014-07-21 2017-10-01
CARDWELL, Ian Director 2010-02-23 2011-12-31
CARTMELL, Simon Christopher Director 1993-06-01 1995-01-01
CHALLONER, Stanley Clive Director 1994-01-31
ELLIOT, John Bell Director 2003-05-14 2006-12-31
HEPBURN, Stuart Director 2012-01-04 2016-05-01
HIGHAM, John Stanley Director 1993-03-03
HUMER, Franz Bernhard Director 1993-05-12
JONES, David John Director 2003-05-14 2009-05-07
JONGEN, Freek Director 2017-10-01 2020-08-25
JORDAN, Stephen Director 2003-05-14 2010-02-23
KELLER, Philip Henry Director 1997-08-02 1997-09-12
KENNEDY, James Director 1993-02-01
LATCHFORD, Richard John Director 2021-05-07 2022-02-19
MCCUBBIN, Ian Director 2013-07-05 2017-03-31
MCINNES, Ian Alexander Thomson, Dr Director 1993-03-03 1996-10-11
MILLER, Timothy John Director 1999-01-01 2000-06-02
MULLINS, Sheila Director 2019-03-22 2020-08-25
O'HARA, Neil Director 2010-02-23 2013-04-09
PADFIELD, John Malcolm, Doctor Director 1994-03-31
PARKES, Philip Edward Director 1993-08-31
PATTESON-BRENT, Erika Director 2020-08-25 2021-09-29
POWER, Joseph James Director 2019-03-22 2020-12-31
PRICE, Barry John, Dr Director 1995-01-01 1995-12-31
PULMAN, David, Doctor Director 1997-01-24 2003-05-14
READSHAW, Ashley Director 1993-09-01 1997-01-17
REYNAUD, Jean Paul Director 2003-05-14 2013-07-12
SIMARD, Regis Jean-Pierre Director 2016-05-18 2019-05-02
TYSON, Timothy Cyril Director 1998-06-01 2002-12-01
VITTY, Graham John Director 1994-11-03
WAIGHTS, Christopher Charles Bolingbroke Director 1994-04-13 1995-01-01
GLAXO GROUP LIMITED Corporate Director 2002-09-11 2003-07-21

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Glaxo Group Limited Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2016-04-06 Active

Filing timeline

Last 20 of 267 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2024-02-20 RESOLUTIONS Resolution
  • 2024-02-20 MA Memorandum articles
  • 2024-02-15 CC04 Statement of companys objects
Date Type Category Description
2026-04-20 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-08-15 AA accounts Accounts with accounts type full
2025-08-04 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-09-23 CH03 officers Change person secretary company with change date PDF
2024-09-22 AA accounts Accounts with accounts type full
2024-09-17 CH01 officers Change person director company with change date PDF
2024-09-17 CH01 officers Change person director company with change date PDF
2024-09-11 AD01 address Change registered office address company with date old address new address PDF
2024-08-16 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-07-18 AD02 address Change sail address company with old address new address PDF
2024-07-08 AP02 officers Appoint corporate director company with name date PDF
2024-02-20 RESOLUTIONS resolution Resolution
2024-02-20 MA incorporation Memorandum articles
2024-02-15 CC04 change-of-constitution Statement of companys objects
2023-08-22 AA accounts Accounts with accounts type full
2023-08-16 CS01 confirmation-statement Confirmation statement with no updates PDF
2023-08-16 PSC05 persons-with-significant-control Change to a person with significant control PDF
2022-10-13 AA accounts Accounts with accounts type full
2022-08-18 CS01 confirmation-statement Confirmation statement with no updates PDF
2022-03-10 AP01 officers Appoint person director company with name date PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
3

last 12 months

Capital events
0

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers

Official Companies House page